WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced Michael “Mick” Farrell, chairman and CEO of Resmed Inc. (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, will be the next chair of the AdvaMed Board of Directors. Farrell will serve a two-year term beginning in January 2026. 

“The entire Board and the global industry AdvaMed represents are excited to have Mick as our chair during a rapidly evolving pace of medtech innovation,” said Scott Whitaker, AdvaMed president and CEO. “Whether in international forums or in the halls of the U.S. Congress, Mick’s enthusiasm for the power of medtech to change lives is endless and contagious. His egalitarian approach is inspiring. As chairman and CEO of Resmed, he is relentlessly committed to helping people sleep better, breathe better, and live longer, healthier lives. We’ll continue to take inspiration from his vision of life-changing medtech for all.”  

“I’m honored by the trust of my peers to serve as chair of AdvaMed,” Farrell said. “It’s a privilege to follow in the footsteps of leaders like Mike Minogue, Ashley McEvoy, and Pete Arduini, who each brought powerful focus to our shared goal of putting patients first, driving innovation, and shaping a better future for health care.   

“As chair, I’ll build on that foundation. I’m focused on accelerating patient-first innovation, advancing digital transformation, and expanding global access to medtech. That means supporting policies that enable care to be delivered everywhere, from hospitals to homes, and personalizing that care for every individual. Together, we can share what’s next in health care, and I’m excited to get to work.” 

Farrell has served on the AdvaMed Board of Directors since 2015. He currently chairs the  International Board Committee and recently joined an AdvaMed CEO delegation to Japan focused on medtech and healthy aging. He also contributed to several Board committees and working groups. 

Farrell was appointed CEO of Resmed and joined its board of directors in March 2013. He became chairman of the board in January 2023. Since joining Resmed in 2000, he has held a range of senior leadership roles, including president of the Americas region from 2011 to 2013, senior vice president of the global sleep apnea business unit from 2007 to 2011, and earlier positions in marketing and business development. Before Resmed, he held roles at Arthur D. Little, Sanofi Genzyme, Dow Chemical, and BHP.  

Farrell also serves as Lead Independent Director at Zimmer Biomet, where he is a member of the Compensation and Management Development Committee and the Quality, Regulatory and Technology Committee. 

Farrell succeeds Peter J. Arduini, president and CEO of GE HealthCare, who served as interim chair of the Board of Directors of AdvaMed for several weeks before his unanimous election as permanent chair in December 2023.  

“Pete’s proven record of leadership over more than three decades in medtech and imaging were critical to AdvaMed at a pivotal period,” Whitaker said. “Under his stewardship, AdvaMed fully integrated its new imaging and digital health tech divisions, securing our position as the only trade association representing the entire medtech and health tech ecosystem, from the companies traditionally considered medtech to tech companies engaging in digital health.  

“Pete brought his sharp understanding of how medical innovation develops today, integrating medtech, imaging, digital health, and AI, for better patient diagnoses and outcomes. The cross-disciplinary lens is the present and future of health care innovation. Pete set us on a clear path to achieve multiple policies necessary for patient access to next-generation medtech and health tech. We’re grateful for his service.” 

Key achievements of Arduini’s tenure include:  

• The firm establishment and integration of AdvaMed’s Imaging and Digital Health Tech divisions, contributing to a surge in membership from 398 companies to 615 companies. 

• Accreditation of AdvaMed by the American National Standards Institute (ANSI) as a Standards Development Organization (SDO). This ensures AdvaMed may convene stakeholders across the global medical technology ecosystem to create consensus-driven standards for patients, providers, regulators, and innovators worldwide.  

• The strongest momentum to date on the longstanding priority of Medicare coverage of FDA-designated and -authorized breakthrough medtech, with overwhelming passage of legislation from a key congressional committee and support of the concept from top Administration leaders.  

• Final Centers for Medicare and Medicaid Services regulations to expand access for millions of Medicare beneficiaries to diagnostic radiopharmaceuticals used to diagnose illnesses including Alzheimer’s, Parkinson’s, heart disease, and certain types of cancer; computed tomography colonography (CTC), a minimally invasive colorectal cancer screening tool; a category of digital mental health treatment devices; and non-opioid treatments for pain relief. 

• A final regulation on the ethylene oxide used to sterilize half of all medical devices in the United States that was more workable than proposed, preserving the critical sterilization method while continuing to protect public health. 

• The biggest ever and first international MedTech Conference (Toronto 2024) and the biggest MedTech Conference in the United States (San Diego 2025). 

Farrell will announce more details on his priorities in early 2026. 

###